State of New Jersey Common Pension Fund D’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Sell
35,539
-4,198
-11% -$124K ﹤0.01% 1489
2026
Q1
$984K Buy
39,737
+51
+0.1% +$1.22K ﹤0.01% 1401
2025
Q4
$926K Sell
39,686
-63,770
-62% -$1.42M ﹤0.01% 1405
2025
Q3
$2.04M Buy
103,456
+25,337
+32% +$521K 0.01% 1292
2025
Q2
$1.7M Sell
78,119
-12,917
-14% -$305K 0.01% 1408
2025
Q1
$2.21M Buy
+91,036
New +$2.05M 0.01% 848
2023
Q2
Sell
-150,943
Closed -$2.5M 1655
2023
Q1
$2.5M Buy
150,943
+14,166
+10% +$234K 0.01% 1011
2022
Q4
$2.54M Buy
+136,777
New +$2.11M 0.01% 980

Other funds holding CPRX

State of New Jersey Common Pension Fund D's CPRX Position: Q2 2026 in Review

State of New Jersey Common Pension Fund D reduced its Catalyst Pharmaceutical (CPRX) stake by 11% in Q2 2026, selling an estimated $124K and leaving 35,539 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

State of New Jersey Common Pension Fund D first reported a position in CPRX in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.54M in Q4 2022. 166 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • State of New Jersey Common Pension Fund D held 35,539 shares of Catalyst Pharmaceutical worth $1.12M as of Q2 2026.
  • State of New Jersey Common Pension Fund D sold 4,198 Catalyst Pharmaceutical shares in Q2 2026, an estimated $124K.
  • Catalyst Pharmaceutical made up ﹤0.01% of State of New Jersey Common Pension Fund D's portfolio in Q2 2026, its #1489 holding.
  • State of New Jersey Common Pension Fund D first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 8 quarters since.
  • State of New Jersey Common Pension Fund D's Catalyst Pharmaceutical position peaked at $2.54M in Q4 2022.
  • 166 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on State of New Jersey Common Pension Fund D's 13F filing for Q2 2026, filed 4 Aug 2026.